Marais, Andre2016-09-092016-09-092016Marais, A 2016, 'The pharmacological management of erectile dysfunction – Update 2016', South African Family Practice, vol. 58, no. 4, pp. 10-14.2078-6190 (print)2078-6204 (online)http://hdl.handle.net/2263/56678Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future, available drugs used in the management of ED.en© 2016 The Author(s). Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0.Cardiovascular diseaseProstaglandinTestosteroneErectile dysfunction (ED)Phosphodiesterase-5 inhibitors (PDE-5)Article